Levosin® (Levosin®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceDioxomethyltetrahydropyrimidine + Sulfadimethoxin + Trimecaine + ChloramphenicolDioxomethyltetrahydropyrimidine + Sulfadimethoxin + Trimecaine + Chloramphenicol
Similar drugsTo uncover
  • Levosin®
    ointment externally 
    NIZHFARM, JSC     Russia
    • Dosage form: & nbspointment for external use
    Composition:

    1 g of ointment contains:

    Active substances: chloramphenicol 10 mg, sulfadimethoxin 40 mg, dioxomethyltetrahydropyrimidine (methyluracil) 40 mg, trimecaine hydrochloride 30 mg,

    Excipients: macrogol - 1500 - 176 mg, macrogol - 400 - 704 mg.

    Description:Ointment from white with yellowish to white with a greenish or kremovatym color shade.
    Pharmacotherapeutic group:Antimicrobial medication combined
    ATX: & nbsp

    D.06.C   Antibiotics in combination with other antimicrobials

    Pharmacodynamics:

    Levosin® is a combined preparation, antimicrobial, anti-inflammatory, analgesic and necrolytic. The drug is active against gram-positive and gram-negative microorganisms, as well as anaerobes.

    Ointment easily penetrates deep into tissues, transporting associated with polyethylene glycol chloramphenicol (levomycetin) and sulfadimethoxin. Due to the high hydration activity of Levosin® in a short time (2-3 days), it usually ensures the elimination of perifocal edema and the purification of the wound from purulent necrotic contents.Methyluracil, which is part of the drug, accelerates the healing of wounds, stimulates cellular defense factors. Trimecaine is a local anesthetic, it acts more strongly and more prolonged than procaine (novocain), low toxicity, does not have an irritant effect.

    Levosin® does not have the ability to cumulate and has no locally irritating properties.

    Pharmacokinetics:The degree of absorption to the systemic circulation after application of the drug is unknown.
    Indications:Purulent wounds (including those infected with mixed microflora: burns, hard-healing ulcers) in the first (purulent-necrotic) phase of the wound process.
    Contraindications:Hypersensitivity to drug components, oppression of bone marrow hematopoiesis, acute intermittent porphyria, deficiency of glucose-6-phosphate dehydrogenase, neonatal period (in children up to 4 weeks the biotransformation of chloramphenicol takes place more slowly than in adults).
    Carefully:Previous treatment with cytostatic drugs or radiation therapy, kidney and liver dysfunction, children age from 4 weeks to 1 year.
    Pregnancy and lactation:The clinical experience of using Levosin® in pregnant and lactating women is limited. Use during pregnancy is possible only if the benefit to the mother exceeds the risk to the fetus. During lactation, either stop using the drug or breast-feeding.
    Dosing and Administration:

    Outwardly. The preparation is impregnated with sterile gauze wipes, which loosely fill the wound. Possible introduction into the purulent cavity through the catheter (drainage tube) with a syringe. In this case, the ointment is preheated to 35-36 ° C. Dressings are performed daily, once a day, until the wound is completely cleared of purulent necrotic masses. At large wound surfaces, the daily dose of ointment in terms of chloramphenicol should not exceed 3 g in adults; in children from 4 weeks and older, the dose should not exceed 50 mg / kg of body weight. 1 cm of ointment contains 1.12 mg of chloramphenicol.

    The duration of treatment depends on the severity and course of the disease.

    Side effects:Allergic reactions: skin rash, itching, hives, angioedema. From the hemopoiesis: rarely - reticulocytopenia, leukopenia, granulocytopenia, thrombocytopenia, erythropenia,agranulocytosis, aplastic anemia.
    Overdose:No cases of overdose of Levosin® ointment were reported.
    Interaction:With simultaneous use with erythromycin, clindamycin, lincomycin, there is a mutual weakening of the effect due to the fact that chloramphenicol can displace these drugs from the bound state or prevent their binding to the 50S subunit of bacterial ribosomes. Reduces the antibacterial effect of penicillins and cephalosporins. Drugs that inhibit bone marrow hematopoies increase the risk of myelosuppression.
    Special instructions:

    In the case of long-term treatment, it is necessary to regularly monitor the pattern of peripheral blood.

    Avoid contact with the eyes.

    When applied to large surfaces with simultaneous intake of ethanol, a disulfiram-like reaction may develop (hyperemia of the skin, tachycardia, nausea, vomiting, reflex coughing, convulsions).

    Effect on the ability to drive transp. cf. and fur:He does not.
    Form release / dosage:
    Ointment for external use.


    Packaging:For 40 g in tubes of aluminum or tubes of polyethylene laminate.Each tube together with instructions for medical use of the drug is placed in a pack of cardboard.
    Storage conditions:At a temperature not exceeding 20 ° C. Keep out of the reach of children.
    Shelf life:2 years. Do not use the drug after the expiration date.
    Terms of leave from pharmacies:Without recipe
    Registration number:P N000546 / 01
    Date of registration:30.05.2007 / 07.02.2014
    Expiration Date:Unlimited
    The owner of the registration certificate:NIZHFARM, JSC NIZHFARM, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp18.02.2018
    Illustrated instructions
      Instructions
      Up